Clinical trials with anti‐angiogenic agents in hematological malignancies
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
New blood vessel formation (angiogenesis) is not only essential for the growth of solid tumors but there is also emerging evidence that progression of hematological malignancies like multiple myeloma, acute leukemias, and myeloproliferative neoplasms, also depends on new blood vessel formation. Anti-angiogenic strategies have become an important therapeutic modality for solid tumors. Several anti-angiogenic agents targeting angiogenesis-related pathways like monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulatory drugs, and proteasome inhibitors have been entered clinical trials or have been already approved for the treatment of hematological malignancies as well and in some instances these pathways have emerged as promising therapeutic targets. This review summarizes recent advances in the basic understanding of the role of angiogenesis in hematological malignancies and clinical trials with novel therapeutic approaches targeting angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“ECs are targeted indirectly for tumor therapy by inhibiting angiogenesis via neutralizing antibodies for VEGF or inhibitors of VEGF activity [34].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Administration of bevacizumab, in combination with cytotoxic chemotherapy, conferred benefits to patients with metastatic colorectal cancer, non-squamous, non-small cell lung cancer and metastatic breast cancer [62-64].”
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“Based on a balance between angiogenic and anti-angiogenic growth factors, a tumor of this size can stay dormant for a very long time period until the so-called angiogenic switch occurs [2].”
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 3×
“Thus, VEGF and VEGFR represent significant anti-cancer therapy targets, which elegantly bypass potential tumor-related treatment barriers [4].”
InfluentialAngiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627 · cited 1×
“Introduction The hypothesis of tumor angiogenesis in malignancies was raised by Judah Folkman: To grow over a certain size of a few millimetres in diameter solid tumors need blood supply from surrounding vessel [1].”
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Additionally, two small-molecule inhibitors targeting VEGFRs and other kinases, sorafenib (NexavarTM, Bayer and Onyx pharmaceuticals) and sunitinib (SutentTM, Pfizer), have been approved based on their efficacy in treating renal cell- and hepatocellular carcinoma [65,66].”
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“Administration of bevacizumab, in combination with cytotoxic chemotherapy, conferred benefits to patients with metastatic colorectal cancer, non-squamous, non-small cell lung cancer and metastatic breast cancer [ 62-64 ].”
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“The role for VEGF in hematogical malignancies has been extensively studied since its isolation from the leukemia cell line HL- 60 in 1989 [25].”
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · cited 1×
“Additionally, two small-molecule inhibitors targeting VEGFRs and other kinases, sorafenib (Nexavar™, Bayer and Onyx pharmaceuticals) and sunitinib (Sutent™, Pfizer), have been approved based on their efficacy in treating renal cell- and hepatocellular carcinoma [ 65 ,66].”
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 1×
“The identification of an acquired somatic mutation in the JAK2 gene, resulting in a valine to phenylalanine substitution at position 617 (JAK2-V617F), has provided new insights into the pathogenesis of BCR-ABL1-negative MPN, being present in most patients with polycythaemia vera (PV) and in about 50% of patients with…”
Research works printed but not linked: 1
- Roccaro AM Hideshima T Raje N Kumar S Ishitsuka K Yasui H Shiraishi N Ribatti D Nico B Vacca A Dammacco F Richardson PG Anderson KC Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Research 2006 66 184 191 10.1158/0008-5472.CAN-05-1195 16397231 · DOI · Paper page
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“ECs are targeted indirectly for tumor therapy by inhibiting angiogenesis via neutralizing antibodies for VEGF or inhibitors of VEGF activity [34].”
BackgroundDogra, P., Adolphi, N. L., Wang, Z., Lin, Y.-S., Butler, K. S., Durfee, P. N., Croissant, J. G., Noureddine, A., Coker, E. N., Bearer, E. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06730-z · Cited by 257
Endothelial Cells in the Tumor Microenvironment
Sobierajska, K., Ciszewski, W. M., Sacewicz-Hofman, I., & Niewiarowska, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_6 · Cited by 179
Nanomedicines for the treatment of hematological malignancies
Deshantri, A. K., Varela-Moreira, A., Ecker, V., Mandhane, S. N., Schiffelers, R. M., Buchner, M., & Fens, M. H. A. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.034 · Cited by 160
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
Dickinson, M., Johnstone, R. W., & Prince, H. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9596-y · Cited by 144
“[177, 179–186].”
Metadata
- Authors
- Medinger, M., & Mross, K.
- Affiliations
- University of Freiburg (DE)
- Corresponding author
- Mross, Klaus
- ORCID
- Medinger, Michael
- Venue
- Journal of Angiogenesis Research
- Publisher
- Publiverse Online SRL
- Published
- 2010
- Volume
- 2
- Issue
- 1
- Pages
- 10
- ISSN
- 2040-2384 (ISSN-L)
- PMC
- PMC2902424
- OpenAlex
- W1987797098
- Cited by
- 40
- References
- 106
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 1 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 4 · 2015: 2 · 2014: 7 · 2012: 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Vascular Cell (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
- Keywords
- angiogenesis, angiogenesis inhibitors, hematologic malignancies, multiple myeloma, acute leukemia, myeloproliferative neoplasms, monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulators, proteasome inhibitors, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trials with anti‐angiogenic agents in hematological malignancies. https://app.cochat.ai/papers/10.1186/2040-2384-2-10
- The paper
- Medinger, M., & Mross, K. (2010). Clinical trials with anti‐angiogenic agents in hematological malignancies. Journal of Angiogenesis Research. https://doi.org/10.1186/2040-2384-2-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.